VEGFA and Hypertension: Arterial hypertension is amongst the most common cardiovascular toxicity in cancer survivors, reported with a prevalence of 37% [26], especially for newly developed target therapy against vascular endothelial growth factor (i.e., Bevacizumab), platelet-derived growth factor (i.e., Sunitinib) and fibroblast growth factor apparently in a dose-dependent manner [27].